These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28756084)

  • 61. Novel drug combinations for the management of relapsed/refractory multiple myeloma.
    Usmani SZ; Lonial S
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S71-7. PubMed ID: 25486960
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.
    Pantani L; Zamagni E; Zannetti BA; Pezzi A; Tacchetti P; Brioli A; Mancuso K; Perrone G; Rocchi S; Tosi P; Cavo M
    Ann Hematol; 2014 Jan; 93(1):123-8. PubMed ID: 23864035
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Age demographics of subjects enrolled in interventional phase 3 multiple myeloma clinical trials.
    Borad A; Saeed H; Toscani M; Barone J; Weber P
    J Oncol Pharm Pract; 2020 Sep; 26(6):1475-1481. PubMed ID: 32611268
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J; Cibeira MT; Rosiñol L
    Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The emperor's new clothes or the current practice of clinical trials for multiple myeloma in the USA.
    Ballester O
    Cancer Invest; 2008 Jun; 26(5):445-7. PubMed ID: 18568765
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of subcutaneous versus intravenous bortezomib in multiple myeloma: a meta-analysis
.
    Hu B; Zhou Q; Wu T; Zhuang L; Yi L; Cao J; Yang X; Wang J
    Int J Clin Pharmacol Ther; 2017 Apr; 55(4):329-338. PubMed ID: 28079515
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
    Richardson P
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern.
    Mohyuddin GR; Banerjee R; Goodman AM
    Eur J Cancer; 2021 Nov; 157():533-535. PubMed ID: 34544634
    [No Abstract]   [Full Text] [Related]  

  • 70. Antibody-based targeting of BCMA in multiple myeloma.
    Morgan GJ; Williams L
    Lancet Oncol; 2020 Feb; 21(2):186-187. PubMed ID: 32007191
    [No Abstract]   [Full Text] [Related]  

  • 71. Cardiac toxicities in multiple myeloma: an updated and a deeper look into the effect of different medications and novel therapies.
    El-Cheikh J; Moukalled N; Malard F; Bazarbachi A; Mohty M
    Blood Cancer J; 2023 May; 13(1):83. PubMed ID: 37208317
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The adverse prognostic impact of advanced age in multiple myeloma.
    Mileshkin L; Prince HM
    Leuk Lymphoma; 2005 Jul; 46(7):951-66. PubMed ID: 16019546
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Survival of ethnic and racial minority patients with multiple myeloma treated with newer medications.
    Pulte ED; Nie L; Gormley N; Goldberg KB; McKee A; Farrell A; Pazdur R
    Blood Adv; 2018 Jan; 2(2):116-119. PubMed ID: 29365319
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Targeted Therapies in Older Adults With Solid Tumors.
    Battisti NML; Decoster L; Williams GR; Kanesvaran R; Wildiers H; Ring A
    J Clin Oncol; 2021 Jul; 39(19):2128-2137. PubMed ID: 34043448
    [No Abstract]   [Full Text] [Related]  

  • 75. Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials.
    Jreich R; Zhang H; Meng Z; Wang F
    J Comp Eff Res; 2024 Jul; 13(7):e230164. PubMed ID: 38869838
    [No Abstract]   [Full Text] [Related]  

  • 76. Incorporating monoclonal antibodies into the management of multiple myeloma.
    Mark TM
    Clin Adv Hematol Oncol; 2017 Dec; 15(12):919-922. PubMed ID: 29315283
    [No Abstract]   [Full Text] [Related]  

  • 77. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.
    Klausen TW; Gregersen H; Abildgaard N; Andersen NF; Frølund UC; Gimsing P; Helleberg C; Vangsted AJ
    Leukemia; 2019 Feb; 33(2):546-549. PubMed ID: 30267010
    [No Abstract]   [Full Text] [Related]  

  • 78. Adequacy of Inclusion of Older Adults in NIH-Funded Phase III Clinical Trials.
    Lockett J; Sauma S; Radziszewska B; Bernard MA
    J Am Geriatr Soc; 2019 Feb; 67(2):218-222. PubMed ID: 30693958
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Older adults in hematologic malignancy trials: Representation, barriers to participation and strategies for addressing underrepresentation.
    Kanapuru B; Singh H; Kwitkowski V; Blumenthal G; Farrell AT; Pazdur R
    Blood Rev; 2020 Sep; 43():100670. PubMed ID: 32241586
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Risk stratified management approaches for smouldering multiple myeloma: clinical research becomes clinical practice.
    Lonial S; Rajkumar SV; Mateos MV
    Lancet Haematol; 2022 Feb; 9(2):e162-e165. PubMed ID: 35114153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.